Get started
Author

Ian Hutchinson

Observed institution: AstraZeneca (United Kingdom)
ORCID: 0000-0001-6118-0509
Observed ORCID: 0000-0001-6118-0509
OpenAlex ID: A5000709034
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2022 · Krista Kinneer, Philipp Wortmann, et al. · Clinical Cancer Research · 74
Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
2022 · Stephen J. Gregson, Kathryn Pugh, et al. · Molecular Cancer Therapeutics · 10
Supplementary Figures S1-10 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2025 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Materials and Methods from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2025 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Figures S11-18 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2025 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Tables S1-4 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2025 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Data from Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
2023 · Stephen J. Gregson, Kathryn Pugh, et al.
Data from Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
2023 · Stephen J. Gregson, Kathryn Pugh, et al.
Data from Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
2023 · Stephen J. Gregson, Kathryn Pugh, et al.
Data from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Data from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Tables S1-4 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Materials and Methods from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Figures S11-18 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Supplementary Figures S1-10 from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2023 · Krista Kinneer, Philipp Wortmann, et al.
Works count: 15
Citation count: 84
H-index: 2
I10-index: 2
Year
Topic
Type